NEW YORK (GenomeWeb) – Rosetta Genomics reported after the close of the market on Wednesday a sharp increase in its revenues for the first half of 2014.

For the six months ended June 30, the miRNA-based molecular diagnostics firm posted $553,779 in revenues, up from $193,012 in the first half of 2013. The company attributed the uptick to growing awareness of and demand for the Rosetta Cancer Origin Test but did not provide details.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.